TYSKA v. ZIMMER BIOMET HOLDINGS, INC.

District Court, D. New Jersey·Decided July 30, 2025·No. 1:24-cv-00817·Unknown

Opinion

THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY CAMDEN VICINAGE

CHRISTOPHER TYSKA,

Plaintiff,

v. Civil No. 24-817 (RMB/EAP)

ZIMMER BIOMET HOLDINGS, INC.; ZIMMER INC.; MICHAEL JASPAN; ABC CORPORATIONS 1-5; JOHN DOES 1-5,

Defendants.

MEMORANDUM ORDER This matter comes before the Court on Plaintiff Christopher Tyska’s (“Plaintiff”) Motion to Quash. ECF No. 39 (“Pl.’s Mot.”). Defendants Zimmer Biomet Holdings, Inc., Zimmer, Inc. and Michael Jaspan (collectively “Defendants”) have opposed the motion. ECF No. 40 (“Defs.’ Opp’n”). Plaintiff filed a reply in support of his motion. ECF No. 41 (“Pl.’s Reply”). The Court has reviewed the parties’ submissions and decides this matter without oral argument pursuant to Federal Rule of Civil Procedure 78 and Local Civil Rule 78.1. For the following reasons, the motion is GRANTED. Factual Background A. Facts According to the Complaint 1. Plaintiff filed this employment action asserting claims of retaliation and wrongful discharge by Defendants Zimmer Biomet Holdings, Inc., Zimmer, Inc. (collectively “Corporate Defendants”) and Michael Jaspan (“Jaspan”). See generally ECF No. 1-1 (“Complaint”). 2. According to the Complaint, the Corporate Defendants develop and market orthopedic reconstructive equipment, including but not limited to, hip and knee implants. Id. ¶ 12. Sales representatives order the necessary medical equipment their customers require, and the Corporate Defendants deliver the equipment to the hospital. Id. ¶ 17. Following delivery, sales representatives inspect the equipment for damage and other potential compromises to ensure proper integrity. See id. 3. According to the Complaint, the Corporate Defendants employed Plaintiff as a medical device sales representative for over fifteen years. Id. ¶ 15. During his employment, Plaintiff

allegedly became one of Corporate Defendants’ top sales representatives and maintained a favorable reputation within the industry. Id. ¶ 18. At all relevant times, Defendant Jaspan served as Plaintiff’s direct supervisor. Id. ¶ 20. 4. On March 17, 2023, Plaintiff allegedly discovered “compromised implants in the hospital supply room.” Id. ¶ 21. Specifically, he noted that the implant tools were “damaged and dirty,” the implant boxes were open, the primary and secondary seals to ensure sterilization were broken or damaged, and the implants were “often mislabeled, damaged, and had missing parts.” Id. ¶¶ 21-23. Plaintiff made similar discoveries on March 31 and April 7, 2023. Id. ¶¶ 37, 41. According to the Complaint, such compromised implants violated U.S. Food and Drug Administration (“FDA”) regulations. Id. ¶¶ 26-31. Plaintiff reported these discoveries to the Corporate Defendants’

management in accordance with the FDA’s Medical Device Reporting regulation. Id. ¶¶ 31-42. Plaintiff asserts that Defendants failed to address his numerous reports and complaints. Id. ¶¶ 35, 38, 40, 42. 5. On April 17, 2023, Plaintiff allegedly discovered that Defendants failed to supply the implant for a hip surgery scheduled to take place that morning. Id. ¶ 44. At the end of that morning’s surgeries, Plaintiff spoke with Logistics/Warehouse Manager Jeff Sippel regarding ongoing patient safety issues, and “Mr. Sippel informed Plaintiff that management was blatantly ignoring Plaintiff’s complaints.” Id. ¶¶ 33, 47. In an effort to “ma[k]e his objections even more clear,” Plaintiff put all of his orders on hold, deducing that patients were better off waiting as opposed to undergoing procedures with compromised equipment. Id. ¶¶ 49-50. However, the Corporate Defendants removed Plaintiff’s hold, and all operations resumed, including continued delivery of compromised equipment. Id. ¶¶ 51, 53. 6. Between April 17, 2023, and May 8, 2023, Plaintiff informed the Corporate Defendants that if they failed to address and correct Plaintiff’s concerns, he would report the matter

to the federal government. Id. ¶ 54. According to the Complaint, Defendants ignored Plaintiff’s ultimatum. Id. ¶ 55. Defendants then retaliatorily accused Plaintiff of committing “‘egregious actions’” and “banned [Plaintiff] from [the] Corporate Defendants, effectively terminating his employment.” Id. ¶ 56. 7. Plaintiff alleges that Defendant Jaspan—“[c]oncerned about revenue and profits”— then tried to rehire Plaintiff. Id. ¶¶ 58-59. Following an unsuccessful phone call with Plaintiff, Jaspan then “set out on a destructive, retaliatory campaign designed to ‘blackball’ Plaintiff from the industry entirely.” Id. ¶¶ 61-68. B. Procedural History Relevant to the Current Dispute 8. On February 12, 2024, Plaintiff filed this action in the New Jersey Superior Court

against Defendants for retaliation in violation of New Jersey Conscientious Employee Protection Act (“CEPA”) (Count One), id. ¶¶ 76-99, and wrongful discharge in violation of public policy (Count Two), id. ¶¶ 100-03. 9. On February 12, 2024, Defendants removed the matter to this Court on grounds of diversity jurisdiction under 28 U.S.C. § 1332. See ECF No. 1 (Notice of Removal). 10. Plaintiff’s discovery responses disclosed that on September 6, 2024, Plaintiff commenced employment with 360Joints as a Consultant earning 100% commission. See ECF No. 40-6, Ex. A (Pl.’s Resp. Interrog. No. 10). During the continuation of Plaintiff’s deposition on December 11, 2024, Defendants’ counsel asked Plaintiff about his role with 360Joints. ECF No. 40- 7, Ex. G (Pl.’s Dep). Based on that testimony, “Defendants understood that, as of August 2024, Plaintiff was not working, but that, as of September 6, 2024, he was working full-time for 360Joints, and that he was in training that was supposed to last for several more months after December 2024.” Defs.’ Opp’n at 7. Defendants contend, however, that two subsequent third-party depositions offered conflicting testimony regarding Plaintiff’s role at 360Joints, calling into question when he started

working there and how much he was working. Id. at 7-10. 11. On April 25, 2025, Defendants notified Plaintiff of their intent to subpoena the president of Plaintiff’s new employer, 360Joints. See ECF No. 40-10, Ex. J (Apr. 25, 2025 Email). The parties participated in a meet-and-confer to discuss the subpoena and the alleged inconsistencies, ECF No. 40-11, Ex. K (Decl. of Brian R. Ellixson) ¶ 2. In response, Plaintiff made a supplemental production of documents on the issue. ECF Nos. 40-12, Ex. L (Feb. 27, 2025 Email); 40-13, Ex. M (Mar. 11, 2025 Email). 12. Because the parties could not reach a resolution of the issue, the Court directed Defendants to serve the subpoena. See ECF No. 36 (Am. Scheduling Order) ¶ 1. The current subpoena seeks the testimony of 360Joints’ president, Misael Ramirez, as well as disclosure of

Free access — add to your briefcase to read the full text and ask questions with AI

TYSKA v. ZIMMER BIOMET HOLDINGS, INC., (D.N.J. 2025).

TYSKA v. ZIMMER BIOMET HOLDINGS, INC. (TYSKA v. ZIMMER BIOMET HOLDINGS, INC.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Graham v. Casey's General Stores
206 F.R.D. 251 (S.D. Indiana, 2002)
In re Domestic Drywall Antitrust Litigation
300 F.R.D. 234 (E.D. Pennsylvania, 2014)